Infusion therapy for Crohn’s disease delivers powerful biologic medications directly into your bloodstream through an IV line. These drugs target specific proteins in the immune system that drive the chronic inflammation behind Crohn’s symptoms. Infusions are typically recommended for moderate-to-severe Crohn’s disease, especially when oral medications haven’t provided enough relief.
How Biologic Infusions Work
Crohn’s disease is fueled by an overactive immune response that attacks the lining of the digestive tract. Biologic infusions contain lab-made antibodies designed to intercept specific immune signals before they can trigger that inflammation. The most established class blocks a protein called TNF-alpha, which acts as an alarm signal that recruits inflammatory cells to the gut wall. By neutralizing TNF-alpha, these drugs can quiet the immune attack and give damaged tissue a chance to heal.
Newer infusion therapies take different approaches. Some block immune cells from traveling to the gut in the first place by targeting adhesion molecules, the “handles” that white blood cells grab onto when migrating into intestinal tissue. Others interrupt a different signaling pathway involving interleukins 12 and 23, proteins that activate the immune cells responsible for chronic gut inflammation. The variety of mechanisms means that if one type of infusion doesn’t work for you, another targeting a different part of the immune system may.
Types of Infusion Drugs for Crohn’s
Three biologic medications are commonly given as IV infusions for Crohn’s disease:
- Infliximab (Remicade) is the original biologic approved for Crohn’s and remains one of the most widely used. It blocks TNF-alpha and is given as an IV infusion lasting at least two hours. You receive loading doses at weeks 0, 2, and 6, then a maintenance infusion every eight weeks.
- Vedolizumab (Entyvio) works differently by preventing inflammatory cells from entering the gut lining. It’s considered “gut-selective,” meaning it targets intestinal inflammation specifically rather than suppressing the immune system broadly.
- Risankizumab (Skyrizi) is a newer option that blocks interleukin-23. Induction consists of three IV infusions of 600 mg at weeks 0, 4, and 8, each lasting at least one hour. After that, you switch to self-administered injections every eight weeks for ongoing maintenance.
Infliximab also has several lower-cost biosimilar versions available. These are near-identical copies of the original drug that have been approved since 2015. Clinical trials and meta-analyses show biosimilars deliver equivalent effectiveness and don’t cause more serious side effects, even in patients who switch from the original. They can significantly reduce cost, which matters for a treatment you may need for years.
What Happens During an Infusion
Most infusions take place in a hospital outpatient center, a gastroenterologist’s office, or a dedicated infusion clinic. You’ll sit in a reclining chair while a nurse places an IV line, typically in your arm. The medication drips slowly through the line over one to two hours, depending on the drug. Infliximab infusions run for at least two hours; risankizumab infusions take at least one hour.
Before the infusion starts, you may receive pre-medications like an antihistamine or acetaminophen to reduce the chance of a reaction. A nurse monitors you throughout the session and usually for a short observation period afterward. Many people bring a book, laptop, or headphones since the process is mostly just sitting and waiting. Plan for a total visit of roughly two to three hours once you factor in check-in, IV setup, the infusion itself, and post-infusion monitoring.
The Induction and Maintenance Schedule
Infusion therapy follows a two-phase pattern. The first phase, called induction, uses a series of closely spaced infusions to build up enough drug in your system to bring inflammation under control. For infliximab, that means three infusions over six weeks (at weeks 0, 2, and 6). For risankizumab, it’s three infusions over eight weeks (at weeks 0, 4, and 8).
Once induction is complete, you move into maintenance therapy: a single infusion every eight weeks to keep the disease in check. This schedule can continue indefinitely as long as the drug keeps working. In the landmark ACCENT I trial of 580 patients, regularly scheduled maintenance infusions every eight weeks led to significantly higher remission rates at nearly every checkpoint through week 46 compared with patients who only received infusions when symptoms flared. That finding established that sticking to a consistent schedule works better than treating only during relapses.
About 58% of patients in that trial responded to the initial infusion within two weeks, and those early responders were the ones who benefited most from ongoing maintenance. If you don’t see a meaningful response after the induction series, your doctor will likely reassess and consider switching to a different biologic class.
Side Effects and Infusion Reactions
The most common concern during treatment is an infusion reaction, which can include flushing, headache, nausea, itching, or mild changes in blood pressure. These reactions occur in roughly 2% of standard infliximab infusions. Severe reactions requiring emergency intervention are rare, estimated between 0.04% and 1% of infusions. A review of approximately 900 pediatric infliximab infusions over two years found zero cases requiring epinephrine or emergency response activation.
Over the longer term, because these drugs suppress parts of the immune system, they can modestly increase your susceptibility to infections. Your care team will typically monitor you with regular blood work and clinic visits to catch any issues early. Another concern is that your body may develop antibodies against the biologic drug itself over time, which can reduce its effectiveness or increase reaction risk. Staying on a consistent maintenance schedule, rather than stopping and restarting, helps reduce that antibody formation.
Infusion Center vs. Home Infusion
Some patients eventually transition to receiving infusions at home, where a nurse comes to administer the IV. This can be more convenient, especially when you’re on a stable maintenance schedule. However, research comparing the two settings found that home infusion patients were significantly more likely to stop therapy, visit the ER for Crohn’s-related problems, or require hospitalization. The difference appeared to stem from less monitoring: home infusion patients had fewer clinic visits and far fewer lab evaluations. Nearly a third of home infusion patients had two or fewer lab assessments in the following year, compared with none of the clinic-based patients.
This doesn’t mean home infusion is inherently unsafe, but it does suggest that if you choose it, staying proactive about follow-up appointments and blood work is important. No formal gastroenterology guidelines exist yet on when home infusion is appropriate, so the decision typically comes down to a conversation with your care team about your stability, tolerance history, and ability to keep up with monitoring on your own.